Editas Medicine, Inc.
For the period ended Sep 2, 2025. Filed Sep 2, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 2, 2025 · Filed Sep 2, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99 · Hematopoietic Stem Cells Program Update
Hematopoietic Stem Cells Program Update
Editas remains committed to progressing its other programs and pipeline. The Company intends to continue work on optimizing candidates for its Hematopoietic Stem Cell (HSC) program but plans to focus its resources on the advancement of its lead EDIT-401 program to human proof-of-concept.
Key Upcoming Planned Milestones
The Company expects to identify and disclose an additional target cell type or tissue by the end of 2025. By mid-2026, it plans to submit an investigational new drug (IND) or clinical trial application (CTA) for EDIT-401, with the goal of achieving in vivo human proof-of-concept data for EDIT-401 by the end of 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.